KBP-042 improves bodyweight and glucose homeostasis with indices of increased insulin sensitivity irrespective of route of administration-Reference-Cited by-同舟云学术

KBP-042 improves bodyweight and glucose homeostasis with indices of increased insulin sensitivity irrespective of route of administration

Published:2015-09 Issue: Volume:762 Page:229-238
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Hjuler Sara T.,Andreassen Kim V.,Gydesen Sofie,Karsdal Morten A.,Henriksen Kim

Publisher

Elsevier BV

Subject

Pharmacology

Reference48 articles.

1. Link between GIP and osteopontin in adipose tissue and insulin resistance;Ahlqvist;Diabetes,2013

2. A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts anti-obesity and anti-diabetic effects in rats;Andreassen;Am. J. Physiol.: Endocrinol. Metab.,2014

3. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM;Carey;Diabetes,1996

4. Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance;Ceperuelo-Mallafre;J. Clin. Endocrinol. Metab 2014 May,2014

5. Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects;Chapman;Obesity,2007

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The dual amylin and calcitonin receptor agonist KBP-336 elicits a unique combination of weight loss, antinociception and bone protection – a novel disease-modifying osteoarthritis drug;Arthritis Research & Therapy;2024-07-12

2. Are insulin sensitizers the new strategy to treat Type 1 diabetes? A long‐acting dual amylin and calcitonin receptor agonist improves insulin‐mediated glycaemic control and controls body weight;British Journal of Pharmacology;2024-02-20

3. Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP-336 and semaglutide results in durable weight loss;European Journal of Pharmacology;2023-09

4. Dual amylin and calcitonin receptor agonist treatment improves insulin sensitivity and increases muscle-specific glucose uptake independent of weight loss;Biomedicine & Pharmacotherapy;2023-08

5. Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin;European Journal of Pharmacology;2023-01